Edition:
United Kingdom

Amarin Corporation PLC (AMRN.OQ)

AMRN.OQ on NASDAQ Stock Exchange Global Market

21.22USD
5:17pm BST
Change (% chg)

$-0.52 (-2.39%)
Prev Close
$21.74
Open
$21.70
Day's High
$21.70
Day's Low
$21.12
Volume
804,137
Avg. Vol
1,608,514
52-wk High
$23.91
52-wk Low
$2.36

Latest Key Developments (Source: Significant Developments)

Amarin Provides Mid-2019 Update, Including Commercialization Plans, FY19 Revenue Guidance
Tuesday, 2 Jul 2019 

July 2 (Reuters) - Amarin Corporation PLC ::AMARIN PROVIDES MID-2019 UPDATE, INCLUDING COMMERCIALIZATION PLANS FOR VASCEPA® AND UPDATES FULL YEAR 2019 REVENUE GUIDANCE.AMARIN CORPORATION PLC - GUIDANCE FOR TOTAL 2019 REVENUE INCREASED TO A RANGE OF $380 TO $420 MILLION FROM $350 MILLION.AMARIN CORPORATION PLC - ENDED JUNE 2019 WITH NO DEBT EXCEPT REMAINING BALANCE ON ITS ROYALTY BEARING INSTRUMENT.AMARIN CORPORATION PLC - PLANS FOR COMMERCIALIZATION OF VASCEPA OUTSIDE OF UNITED STATES REMAIN UNCHANGED.AMARIN CORPORATION PLC - VASCEPA SNDA PDUFA GOAL DATE ON-TRACK FOR SEPTEMBER 28, 2019.AMARIN CORPORATION PLC - TO DATE, FDA HAS NOT INFORMED AMARIN AS TO WHETHER IT PLANS TO CONVENE AN ADVISORY COMMITTEE MEETING (ADCOM) TO REVIEW SNDA.AMARIN CORPORATION PLC - AMARIN ENDED JUNE 2019 WITH CASH AND CASH EQUIVALENTS OF APPROXIMATELY $221 MILLION.  Full Article

FDA Grants Priority Review To Amarin Corp's Vascepa
Wednesday, 29 May 2019 

May 29 (Reuters) - Amarin Corporation PLC ::U.S. FDA GRANTS PRIORITY REVIEW FOR VASCEPA® (ICOSAPENT ETHYL) SUPPLEMENTAL NEW DRUG APPLICATION SEEKING CARDIOVASCULAR RISK REDUCTION INDICATION.AMARIN CORPORATION PLC - PDUFA DATE ASSIGNED IS SEPTEMBER 28, 2019, FOUR MONTHS SOONER THAN EXPECTED.AMARIN CORPORATION PLC - AMARIN IS ACCELERATING PLANS FOR COMMERCIAL EXPANSION, BASED ON PRIORITY REVIEW DESIGNATION.  Full Article

Amarin Provides Preliminary 2018 Results And 2019 Outlook
Friday, 4 Jan 2019 

Jan 4 (Reuters) - Amarin Corporation PLC ::AMARIN PROVIDES PRELIMINARY 2018 RESULTS AND 2019 OUTLOOK.SEES FY 2018 REVENUE $224 MILLION TO $228 MILLION.SEES Q4 2018 REVENUE $72 MILLION TO $76 MILLION.FY2018 REVENUE VIEW $221.4 MILLION -- REFINITIV IBES DATA.Q4 REVENUE VIEW $69.4 MILLION -- REFINITIV IBES DATA.2019 NET TOTAL REVENUE PROJECTED TO INCREASE BY MORE THAN 50% TO APPROXIMATELY $350 MILLION.SNDA SEEKING LABEL EXPANSION FOR VASCEPA IN U.S. ANTICIPATED TO BE SUBMITTED BY END OF Q1 2019.DO NOT EXPECT VASCEPA COVERAGE BY MOST PAYERS TO CHANGE DRAMATICALLY IN 2019 COMPARED TO CURRENT COVERAGE.SUBMISSION OF SNDA IS NOT ANTICIPATED UNTIL LATE IN Q1 2019..  Full Article

Amarin Prices Public Offering Of Its ADSs For Gross Proceeds Of about $200 Mln
Tuesday, 27 Nov 2018 

Nov 26 (Reuters) - Amarin Corporation PLC ::AMARIN PRICES PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES.AMARIN CORPORATION PLC - PRICING OF UNDERWRITTEN PUBLIC OFFERING OF ITS ADSS FOR GROSS PROCEEDS OF APPROXIMATELY $200.0 MILLION.AMARIN CORPORATION PLC - OFFERING IS EXPECTED TO CLOSE ON OR ABOUT NOVEMBER 29, 2018.  Full Article

Amarin Corporation Says ‍Ministry Of Public Health In Lebanon Approved Vascepa
Wednesday, 21 Mar 2018 

March 21 (Reuters) - Amarin Corporation Plc ::AMARIN ANNOUNCES FIRST MIDDLE EAST APPROVAL FOR VASCEPA®.AMARIN CORPORATION PLC - ‍MINISTRY OF PUBLIC HEALTH IN LEBANON HAS APPROVED VASCEPA​.AMARIN - ‍REV POTENTIAL FOR VASCEPA OUTSIDE U.S. SEEN TO BE RELATIVELY MODEST UNTIL ADDITIONAL COUNTRIES​ APPROVAL.AMARIN CORPORATION PLC - ‍APPROVED AS PRESCRIPTION MEDICATION AS ADJUNCT TO DIET TO REDUCE TG LEVELS IN ADULT PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA​.  Full Article

Amarin Reports Fourth Quarter Loss Of $0.08 Per Share
Tuesday, 27 Feb 2018 

Feb 27 (Reuters) - Amarin Corporation Plc ::AMARIN REPORTS RECORD FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES UPDATE ON OPERATIONS.QTRLY NET PRODUCT REVENUE $53.5 MILLION VERSUS $38.4 MILLION.QTRLY LOSS PER SHARE $0.08.SAYS ‍AMARIN ESTIMATES THAT ITS NET PRODUCT REVENUE IN Q1 2018 WILL BE BETWEEN $45 MILLION AND $48 MILLION​.‍Q2 2018 RESULTS WILL REBOUND ON A CONSECUTIVE QUARTER BASIS WITH NET PRODUCT REVENUE ANTICIPATED IN Q2 2018 OF $55 MILLION OR MORE​.Q4 EARNINGS PER SHARE VIEW $-0.05, REVENUE VIEW $51.9 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Amarin Corp Sees Full-Year 2017 Net Product Revenue Estimated Between $177 Mln-$180 Mln​
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Amarin Corp Plc ::AMARIN PROVIDES PRELIMINARY 2017 RESULTS AND PROVIDES 2018 OUTLOOK.AMARIN CORPORATION PLC SEES ‍UNAUDITED FULL-YEAR 2017 NET PRODUCT REVENUE ESTIMATED BETWEEN $177 AND $180 MILLION​.AMARIN - ‍WITHOUT ADJUSTMENT FOR IMPACT OF REDUCE-IT RESULTS, CO ESTIMATES 2018 NET PRODUCT REVENUE FROM VASCEPA WILL GROW TO ABOUT $230 MILLION​.AMARIN - ‍ESTIMATES IN EACH QUARTER OF 2018 NET PRODUCT REVENUE SHOULD GROW APPROXIMATELY 30% OR MORE AS COMPARED TO SAME QUARTER IN 2017​.AMARIN CORPORATION PLC - ‍ESTIMATES THAT ITS NET PRODUCT REVENUE IN Q1 2018 WILL BE BETWEEN $45 AND $48 MILLION​.AMARIN CORPORATION PLC - ‍ANTICIPATES THAT Q2 2018 RESULTS WILL REBOUND WITH NET PRODUCT REVENUE ANTICIPATED IN Q2 2018 OF $55 MILLION OR MORE​.  Full Article

Amarin Says It Is On Track To Report Top-Line Results From REDUCE-IT Cardiovascular Outcomes Study
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Amarin Corporation Plc ::AMARIN ANNOUNCES REDUCE-IT CARDIOVASCULAR OUTCOMES STUDY FINAL PATIENT VISITS TO COMMENCE IN MARCH 2018.AMARIN CORPORATION PLC - CONFIRMED IT IS ON TRACK TO REPORT TOP-LINE RESULTS FROM REDUCE-IT CARDIOVASCULAR OUTCOMES STUDY BEFORE END OF Q3 2018.AMARIN - ‍MAINTAINS GUIDANCE THAT ONSET OF TARGETED 1,612TH PRIMARY MACE IN STUDY IS PROJECTED TO OCCUR BEFORE END OF Q1 2018​.  Full Article

Amarin reports Q3 loss per share $0.04
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Amarin :Amarin reports third quarter 2017 financial results and provides update on operations.Q3 loss per share $0.04.Q3 earnings per share view $-0.05 -- Thomson Reuters I/B/E/S.Amarin Corporation Plc - Qtrly net product revenue $47.1 million versus $32.4 million​.  Full Article

Amarin names Mark Salyer chief commercial officer
Wednesday, 13 Sep 2017 

Sept 13 (Reuters) - Amarin Corporation Plc :Amarin appoints Mark W. Salyer to new position of chief commercial officer.Amarin remains on track to reach record product revenues of $165 to $175 million in 2017​.Most recently, Salyer was at Teva Pharmaceuticals as executive vice president and general manager of Teva Respiratory LLC​.  Full Article

Amarin's Vascepa cuts occurrence of serious heart problems 30 pct -study

March 18 A high dose of Amarin Corp's Omega-3 drug Vascepa significantly reduced the occurrence of first and subsequent heart attacks, strokes and other serious heart problems in high-risk patients already taking cholesterol medication by even more than initially reported, according to data presented on Monday.